ENTPD1 and glioblastoma: Along similar lines, Entpd1 or Nte5 deletion as well as pharmacological or antibody-mediated inhibition of CD39 and/or CD73 have been consistently associated with restored NK cell activity and improved tumor control in numerous preclinical models of malignancy, including melanoma [162], sarcoma [163], glioblastoma [53], as well as prostate [163], breast [164], and colorectal cancer [165, 166].